FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizonal rule
CBER links to product areas Blood Vaccines Cellular/Gene Therapy Tissue Devices
CBER links Products Industry Healthcare Reading Room Meetings What's New
horizonal rule

Recall of Automated Blood Cell Separators, Baxter Fenwal, Open and Closed System Apheresis Kits

horizonal rule

DATE RECALL INITIATED:

May 7, 2002

PRODUCT / LOT NUMBER / EXPIRATION DATE

Baxter Fenwal Open System Apheresis Kit - H01G23055 2-28-2003
Baxter Fenwal Semi-Closed System Apheresis Kit - H01G09104 3-6-2003
Baxter Fenwal Closed System Apheresis Kit - H01G02117 1-31-2003

RECALLING FIRM

Baxter Healthcare Corporation
Fenwal Division
Round Lake, IL

MANUFACTURER:

Baxter Healthcare Corporation
Mountain Home, AR

REASON:

Baxter Healthcare Corporation has become aware of a restriction in the Y-site located above the separation container that can cause pressure alarms during priming of the Apheresis Kit and possibly during the collection procedure. This restriction may damage red cell during the collection procedure. The CS-3000 Blood Cell Separator is designed to alarm when pressure restrictions occur during priming or the collection procedure. These alarms alert the CS-3000 Operator of a restriction within the Apheresis Kit. The potential issues associated with this restriction are alarms during priming and collection, difficulty completing a procedure, and impaired red blood cell flow. The flow restriction through the Y-site would affect a small number of Apheresis Kits and would be apparent to the CS-3000 operator via alarms during the priming and run procedures. Consignees have been asked to contact the manufacturer to arrange for product return. .

horizonal rule

The information in this listing reflects CBER's best efforts to communicate information that has been reported to FDA. Its accuracy and comprehensiveness cannot be guaranteed.

 

 
horizonal rule